

# **Global Injectable Drug Delivery Market – Focus on Devices, Competitive Landscape and Country - Analysis and Forecast (2018-2025)**

<https://marketpublishers.com/r/GE35725F2814EN.html>

Date: April 2018

Pages: 327

Price: US\$ 4,599.00 (Single User License)

ID: GE35725F2814EN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

The global healthcare scenario is changing rapidly owing to the rising geriatric population as well as the increasing prevalence of diseases. As per the WHO statistics, the global elderly population (aged 65 years and over) was 562 million in 2012 and it increased by 55 million in 2015. The rising prevalence of various chronic and autoimmune diseases had a profound effect on the global healthcare scenario. The WHO further states that the global prevalence of diabetes, which is one of the chronic diseases, increased to 8.5% in adults over the age of 18 years in 2014, from 4.7% in 1980. These factors have led to an escalated demand for improved treatment and diagnostic services as diagnosis is the very first and crucial step of treating any ailment. The treatment of these chronic diseases involves the frequent administration of drugs, especially biologics and biosimilars. Initially hypodermic needles and syringes were used. Nowadays novel ways to administer drug have been developed like needle free injectors, autoinjectors, pen injectors & prefilled syringes.

The injectable drug delivery devices market includes devices, such as auto-injectors, pen injectors and needle free injection technology. The market consists of various device products which can be used for various routes of administration, such as intravenous, subcutaneous/ intradermal, intra-peritoneal, intra-muscular and others.

These devices are being used for the administration of various medications especially for the biological products and proteins, such as insulin. The market analysis includes an in-depth examination of the key ecosystem players, and the key strategies and

developments taking place in this market. Additionally, it includes market dynamics (market drivers, opportunities, and challenges), and industry analysis.

The purpose of the study is to gain a holistic view of the global injectable drug delivery market in terms of various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the injectable drug delivery market. The market has been segmented into 'devices', 'end-user', 'route of administration' and 'geographical regions'. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the significant parameters that must be taken into consideration before entering the market.

This research report aims at answering questions related to various aspects of the global market with the help of the key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global injectable drug delivery market, and assesses the factors governing the same.

The answers to the following key questions can be derived from this report:

What are the major market drivers, challenges, and opportunities in the global injectable drug delivery market?

How did the needle less technology evolve, and what is its scope in the future?

What were the market shares of the leading segments, and sub-segments of the global injectable drug delivery market in 2016 and what will be the value after 2025?

How will each segment of the global injectable drug delivery market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2025?

What are the influencing factors that may affect the market share of the key players?

What are the key developmental strategies implemented by the key players to

stand out in this market?

What will be the growth rate of the pen injectors and autoinjector devices during the forecast period?

Which product segment is expected to register the highest CAGR for the injectable drug delivery market?

How will the homecare segment among the end users grow from 2018 to 2025?

Which geographical location will contribute to the highest sales of the injectable drug delivery devices during the forecast period?

The key players for the market are Antares Pharma, Becton Dickinson and Company, Baxter International AG, Elcam Medical, Eli-Lilly, Sanofi, Gerresheimer AG, PharmaJet, Injex Pharma, and Schott AG, among others.

## Contents

### EXECUTIVE SUMMARY

### 1 MARKET OVERVIEW

- 1.1. Introduction
- 1.2. History of Injectable Drug Delivery Systems
- 1.3. Onset of Prefilled-Syringes
- 1.4. Introduction of Needle-Free Technology
- 1.5. Advantages of Prefilled Syringes Over Traditional Vial & Syringe System
- 1.6. Prefilled Syringes: Manufacturing and Packaging Challenges
- 1.7. Components of Prefilled Syringes
- 1.8. Benefits of Prefilled Syringes to the Pharmaceutical Companies
- 1.9. Rising Prevalence of Diabetes
- 1.10. Diabetes Prevalence in Different Countries (2017 Estimates)
- 1.11. Rising Prevalence of Diabetes and Use of Insulin Delivery Devices

### 2 MARKET DYNAMICS

- 2.1. Overview
- 2.2. Impact Analysis
- 2.3. Market Drivers
- 2.4. Market Restraints
- 2.5. Market Opportunities

### 3 COMPETITIVE LANDSCAPE

- 3.1. Key Developments & Strategies
- 3.2. Recent Market Development Strategy Snapshot Analysis
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Bargaining Power of Buyers
  - 3.3.3. Threat of New Entrant
  - 3.3.4. Threat of Substitute
  - 3.3.5. Intensity of Competitive Rivalry
- 3.4. Market Share Analysis
  - 3.4.1. Market Share Analysis, Pen and Auto Injectors
  - 3.4.2. Market Share Analysis, Prefilled

- 3.4.3. Market Share Analysis, Needle Free Injectors
- 3.5. Assumptions & Limitations for Analysis & Forecast of the Global Injectable Drug Delivery Market

## **4 INDUSTRY INSIGHTS**

- 4.1. Patent Landscape
- 4.2. Legal Requirements and Regulations
- 4.3. Consortiums, Associations and Regulatory Bodies

## **5 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE**

- 5.1. Introduction
- 5.2. Needle Free Injectors (Gas-based, Spring-Based and Others)
  - 5.2.1. Global Needle Free Injector Market, By Region
- 5.3. Auto-Injectors (Reusable & Disposable)
  - 5.3.1 Global Auto-Injectors Market, By Region
- 5.4. Pen Injectors (Reusable & Disposable)
  - 5.4.1. Pen Injectors for Insulin
  - 5.4.2. Global Pen Injectors Market, By Region
- 5.5. Prefilled Syringes
  - 5.5.1. Global Prefilled Syringe Market, By Region
  - 5.5.2. Glass Prefilled Syringes
  - 5.5.3. Plastic Prefilled Syringes
  - 5.5.4. Single Chamber Prefilled Syringes
    - 5.5.4.1. Advantages of Hyaluronic Method of Single Chamber Prefilled Syringes
- Filling
  - 5.5.5. Dual Chamber Prefilled Syringes
    - 5.5.5.1 Some of the Marketed Dual Chambered Prefilled Syringes
  - 5.5.6. Conventional Prefilled Syringe
  - 5.5.7. Some of the lyophilized drugs which are used in prefilled syringe format
  - 5.5.8. Safety Prefilled Syringes
    - 5.5.8.1. Marketed Prefilled Safety Syringes
  - 5.5.9. Customized Prefilled Syringes
- 5.6. Wearable Injectors (Qualitative)

## **6 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER**

- 6.1. Different Types of End User

- 6.1.1. Overview
- 6.1.2. Home Based
- 6.1.3. Hospital
- 6.1.4. Ambulatory Care
- 6.1.5. Clinics/Physician Offices
- 6.1.6 Others
- 6.2. Global Prefilled Syringes Market, by End Users
- 6.3. Global Needle Free Injector Market, by End Users
- 6.4. Global Auto-Injectors Market, by End Users
- 6.5. Global Pen Injection Market, by End Users

## **7 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION**

- 7.1. Overview
- 7.2. Different Route of Administration (Intravenous, Subcutaneous, intramuscular and Others)
- 7.3. Global Injectable Drug Delivery Market, By Route of Administration

## **8 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION**

- 8.1. Geographical Scenario
- 8.2. North America
  - 8.2.1 The U.S.
  - 8.2.2. Canada
- 8.3. Europe
  - 8.3.1. The U.K.
  - 8.3.2. Germany
  - 8.3.3. France
  - 8.3.4. Italy
  - 8.3.5. Spain
  - 8.3.6. Netherlands
  - 8.3.7. Switzerland
  - 8.3.8. Belgium
  - 8.3.9. Poland
  - 8.3.10. Austria
  - 8.3.11. Turkey
  - 8.3.12. Rest of Europe
- 8.4. Asia Pacific (APAC)

- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. Australia
- 8.4.4. South Korea
- 8.4.5. India
- 8.4.6. Malaysia
- 8.4.7. Indonesia
- 8.4.8. Rest of Asia Pacific
- 8.5. Latin America
  - 8.5.1. Brazil
  - 8.5.2. Mexico
  - 8.5.3. Argentina
  - 8.5.4. Rest of Latin America
- 8.6. Rest of the World (RoW)
  - 8.6.1. K.S.A
  - 8.6.2. Russia
  - 8.6.3. South Africa
  - 8.6.4. RoW

## **9 COMPANY PROFILES**

### **9.1. ALKERMES PUBLIC LIMITED COMPANY**

- 9.1.1. Overview
- 9.1.2. Product Portfolio
- 9.1.3. Financials
  - 9.1.3.1. Financial Summary
- 9.1.4. SWOT Analysis

### **9.2. Antares Pharma**

- 9.2.1. Overview
- 9.2.2. Product Portfolio
- 9.2.3. Financials
  - 9.2.3.1. Financial Summary
- 9.2.4. SWOT Analysis

### **9.3. Baxter International Inc.**

- 9.3.1. Overview
- 9.3.2. Product Portfolio
- 9.3.3. Financials
  - 9.3.3.1. Financial Summary
- 9.3.4. SWOT Analysis

#### 9.4. Becton, Dickinson and Company

##### 9.4.1. Overview

##### 9.4.2. Product Portfolio

##### 9.4.3. Financials

##### 9.4.3.1. Financial Summary

##### 9.4.4. SWOT Analysis

#### 9.5. Elcam Medical

##### 9.5.1. Overview

##### 9.5.2. Product Portfolio

##### 9.5.3. Corporate Summary

##### 9.5.4. SWOT Analysis

#### 9.6. Eli-Lilly and Company

##### 9.6.1. Overview

##### 9.6.2. Product Portfolio

##### 9.6.3. Financials

##### 9.6.3.1. Financial Summary

##### 9.6.4. SWOT Analysis

#### 9.7. Gerresheimer AG

##### 9.7.1. Overview

##### 9.7.2. Product Portfolio

##### 9.7.3. Financials

##### 9.7.3.1. Financial Summary

##### 9.7.4. SWOT Analysis

#### 9.8. Injex Pharma GmbH

##### 9.8.1. Overview

##### 9.8.2. Product Portfolio

##### 9.8.3. Corporate Summary

##### 9.8.4. SWOT Analysis

#### 9.9. Novartis AG

##### 9.9.1. Overview

##### 9.9.2. Product Portfolio

##### 9.9.3. Financials

##### 9.9.3.1. Financial Summary

##### 9.9.4. SWOT Analysis

#### 9.10. NOVO NORDISK

##### 9.10.1. Overview

##### 9.10.2. Product Portfolio

##### 9.10.3. Financials

##### 9.10.3.1. Financial Summary



- 9.10.4. SWOT Analysis
- 9.11. Pfizer, Inc.
  - 9.11.1. Overview
  - 9.11.2. Product Portfolio
  - 9.11.3. Financials
    - 9.11.3.1. Financial Summary
  - 9.11.4. SWOT Analysis
- 9.12. PharmaJet
  - 9.12.1. Overview
  - 9.12.2. Product Portfolio
  - 9.12.3. Corporate Summary
  - 9.12.4. SWOT Analysis
- 9.13. SANOFI
  - 9.13.1. Overview
  - 9.13.2. Product Portfolio
  - 9.13.3. Financials
    - 9.13.3.1. Financial Summary
  - 9.13.4. SWOT Analysis
- 9.14. Schott AG
  - 9.14.1. Overview
  - 9.14.2. Product Portfolio
  - 9.14.3. Financials
    - 9.14.3.1. Financial Summary
  - 9.14.4. SWOT Analysis
- 9.15. Terumo Corporation
  - 9.15.1. Overview
  - 9.15.2. Product Portfolio
  - 9.15.3. Financials
    - 9.15.3.1. Financial Summary
  - 9.15.4. SWOT Analysis
- 9.16. Teva Pharmaceutical Industries Limited.
  - 9.16.1. Overview
  - 9.16.2. Product Portfolio
  - 9.16.3. Financials
    - 9.16.3.1. Financial Summary
  - 9.16.4. SWOT Analysis
- 9.17. Vetter Pharma-Fertigung GmbH & Co. KG
  - 9.17.1. Overview
  - 9.17.2. Product Portfolio

- 9.17.3. Corporate Summary
- 9.17.4. SWOT Analysis
- 9.18. West Pharmaceutical Services, Inc.
  - 9.18.1. Overview
  - 9.18.2 Product Portfolio
  - 9.18.3. Financials
    - 9.18.3.1. Financial Summary
  - 9.18.4. SWOT Analysis
- 9.19. Ypsomed Holding AG
  - 9.19.1. Overview
  - 9.19.2 Product Portfolio
  - 9.19.3. Financials
    - 9.19.3.1. Financial Summary
  - 9.19.4. SWOT Analysis

## **10 REPORT SCOPE & METHODOLOGY**

- 10.1. Scope of the Report
- 10.2. Market Segmentation
- 10.3. Research Methodology
  - 10.3.1. Primary Research
  - 10.3.2 Secondary Research
  - 10.3.3. Key Data Points From Primary Sources
  - 10.3.4. Data Triangulation
  - 10.3.5. Top-Down Approach (Segmental Analysis)
  - 10.3.6. Bottom-Up Approach (Segmental Analysis)
- 10.4. Assumptions and Limitations

## List Of Tables

### LIST OF TABLES

**1 KEY PLAYERS IN THE MARKET**

**2 IMPACT OF MARKET DRIVERS**

**3 IMPACT OF MARKET RESTRAINTS**

**4 COMPONENTS OF PREFILLED SYRINGES**

**5 NUMBER OF DIABETICS WORLDWIDE AND AS PER REGION IN 2017 AND 2045  
(20-79 YEARS)**

**6 COMPARATIVE PREVALENCE OF DIABETES IN DIFFERENT COUNTRIES (20-79  
YEARS)**

**7 IMPACT ANALYSIS OF MARKET DYNAMICS**

**8 REGION-WISE PERCENTAGE OF TOTAL POPULATION AGED 65 YEARS &  
ABOVE: 2015 & 2030**

**9 FACTORS AFFECTING THE BARGAINING POWER OF BUYER**

**10 FACTORS AFFECTING THREAT OF NEW ENTRANT**

**11 FACTORS AFFECTING THE THREAT OF SUBSTITUTE**

**12 FACTORS AFFECTING THE INTENSITY OF COMPETITIVE RIVALRY**

**13 PATENT LANDSCAPE**

**14 CONSORTIUMS, ASSOCIATIONS AND REGULATORY BODIES**

**15 LIST OF SOME OF THE MARKETED PRODUCTS**

**16 DIFFERENT TYPES OF INSULIN PEN INJECTORS IN MARKET**

**17 REGIONAL PEN INJECTORS MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**18 REGIONAL PREFILLED SYRINGE MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**19 REGIONAL PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION UNITS)**

**20 LIST OF SOME DUAL CHAMBER PREFILLED SYRINGES**

**21 LIST OF SOME LYOPHILIZED DRUGS WHICH ARE USED IN PREFILLED SYRINGE FORMAT**

**22 LIST OF SOME RECENTLY MARKETED PREFILLED SAFETY SYRINGES TECHNOLOGIES**

**23 GLOBAL DRUG DELIVERY MARKET BY ROUTE OF ADMINISTRATION (2016-2025)**

**24 PERCENTAGES OF POPULATION AGED 60 YEARS AND ABOVE**

**25 ALKERMES PUBLIC LIMITED COMPANY: OVERVIEW**

**26 ANTARES PHARMA: OVERVIEW**

**27 BAXTER INTERNATIONAL INC.: OVERVIEW**

**28 BECTON DICKINSON AND COMPANY: OVERVIEW**

**29 ELCAM MEDICAL: OVERVIEW**

**30 ELI-LILLY AND COMPANY: OVERVIEW**

**31 GERRESHEIMER AG: OVERVIEW**

**32 INJEX PHARMA GMBH: OVERVIEW**

**33 NOVARTIS AG: OVERVIEW**

**34 NOVO NORDISK: OVERVIEW**

**35 PFIZER, INC.: OVERVIEW**

**36 PHARMAJET: OVERVIEW**

**37 SANOFI: OVERVIEW**

**38 SCHOTT AG: OVERVIEW**

**39 TERUMO CORPORATION: OVERVIEW**

**40 TEVA PHARMACEUTICALS INDUSTRIES LIMITED.: OVERVIEW**

**41 VETTER PHARMA-FERTIGUNG GMBH & CO. KG: OVERVIEW**

**42 WEST PHARMACEUTICAL SERVICES, INC.: OVERVIEW**

**43 YPSOMED HOLDING AG: OVERVIEW**

## List Of Figures

### LIST OF FIGURES

- 1 CHRONIC CONDITIONS: KEY STATISTICS: 2016**
- 2 THE GLOBAL INJECTABLE DRUG DELIVERY MARKET (\$MILLION)**
- 3 TYPES OF INJECTOR DEVICES**
- 4 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016**
- 5 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICES, 2025**
- 6 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USERS, 2016**
- 7 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USERS, 2025**
- 8 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2016**
- 9 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2025**
- 10 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2016**
- 11 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2025**
- 12 VARIOUS TYPES OF INJECTABLE DRUG DELIVERY DEVICES**
- 13 LIMITATIONS OF HYPODERMIC NEEDLES**
- 14 KEY MILESTONES IN HISTORY OF SYRINGES**
- 15 THE KEY ADVANTAGES OF NEEDLE-FREE TECHNOLOGY**
- 16 ADVANCEMENTS IN INJECTABLE DRUG DELIVERY TECHNOLOGY**

**17 ADVANTAGES OF PREFILLED SYRINGES**

**18 DIABETES STATISTICS**

**19 DRIVERS RESTRAINTS AND OPPORTUNITIES**

**20 PER DAY COST SAVINGS VS. HOSPITAL**

**21 SHARE OF THE KEY STRATEGIES IN THE GLOBAL INJECTABLE DRUG DELIVERY MARKET**

**22 PORTER'S FIVE FORCES ANALYSIS**

**23 GLOBAL INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$ MILLION)**

**24 SEGMENTATION OF GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE**

**25 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2016-2025 (\$MILLION)**

**26 GLOBAL NEEDLE FREE INJECTOR MARKET, 2016-2025 (\$ MILLION)**

**27 GLOBAL NEEDLE FREE INJECTOR MARKET, BY TYPE, 2016-2025 (\$MILLION)**

**28 ADVANTAGES AND DISADVANTAGES OF NEEDLE FREE INJECTORS**

**29 TYPES OF NEEDLE FREE INJECTORS**

**30 GLOBAL GAS-BASED NEEDLE-FREE INJECTORS MARKET, 2016-2025 (\$MILLION)**

**31 GLOBAL SPRING-BASED NEEDLE-FREE INJECTORS MARKET, 2016-2025 (\$MILLION)**

**32 GLOBAL OTHERS NEEDLE-FREE INJECTORS MARKET, 2016-2025 (\$MILLION)**

**33 GLOBAL AUTO-INJECTOR MARKET, 2016-2025 (\$ MILLION)**

**34 GLOBAL AUTO-INJECTOR MARKET, BY TYPE, 2016-2025 (\$MILLION)**

**35 TYPES OF PEN INJECTORS**

**36 GLOBAL PEN INJECTOR MARKET, 2016-2025 (\$ MILLION)**

**37 GLOBAL PEN INJECTOR MARKET, BY TYPE, 2016-2025 (\$MILLION)**

**38 GLOBAL PREFILLED SYRINGE MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**39 GLOBAL PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION)**

**40 GLOBAL GLASS PREFILLED SYRINGES MARKET, BY VALUE, 2016-2025 (\$ MILLIONS)**

**41 GLOBAL GLASS PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION)**

**42 GLOBAL PLASTIC PREFILLED SYRINGE MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**43 GLOBAL PLASTIC PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION)**

**44 GLOBAL SINGLE CHAMBERED PREFILLED SYRINGE MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**45 GLOBAL PLASTIC PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION)**

**46 GLOBAL DUAL CHAMBERED PREFILLED SYRINGE MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**47 GLOBAL DUAL CHAMBERED PREFILLED SYRINGE MARKET, BY VOLUME, 2016-2025 (MILLION)**

**48 GLOBAL CUSTOMIZED PREFILLED SYRINGES MARKET, BY VALUE AND VOLUME, 2016-2025 (\$ MILLIONS)**



**49 GLOBAL CUSTOMIZED PREFILLED SYRINGE MARKET, BY VOLUME,  
2016-2025 (MILLION)**

**50 TYPES OF END USERS**

**51 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USERS  
(2016-2025)**

**52 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY HOME BASED  
TREATMENT (2016-2025)**

**53 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY HOSPITAL (2016-2025)**

**54 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY AMBULATORY CARE  
(2016-2025)**

**55 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY CLINICS/PHYSICIAN  
OFFICES (2016-2025)**

**56 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY OTHERS (2016-2025)**

**57 GLOBAL PREFILLED SYRINGES MARKET, BY END USERS (2016-2025)**

**58 GLOBAL NEEDLE FREE MARKET, BY END USERS 2016-2025)**

**59 GLOBAL AUTO- INJECTORS MARKET, BY END USERS (2016-2025)**

**60 GLOBAL PEN INJECTION MARKET, BY END USERS (2016-2025)**

**61 DIFFERENT ROUTES OF ADMINISTRATION**

**62 GLOBAL DRUG DELIVERY MARKET BY ROUTE OF ADMINISTRATION  
(2016-2025)**

**63 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION**

**64 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2016-2025  
(\$MILLION)**

**65 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**66 NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2016-2025 (\$MILLION)**

**67 THE U.S. INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**68 THE U.S. INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025 (\$MILLION)**

**69 CANADA INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**70 CANADA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE 2016-2025 (\$MILLION)**

**71 EUROPE INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**72 THE U.K. INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**73 THE U.K. INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025 (\$MILLION)**

**74 GERMANY INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**75 GERMANY INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025 (\$MILLION)**

**76 FRANCE INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**77 FRANCE INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025 (\$MILLION)**

**78 ITALY INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**79 ITALY INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025 (\$MILLION)**

**80 SPAIN INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**81 SPAIN INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025  
(\$MILLION)**

**82 NETHERLANDS INJECTABLE DRUG DELIVERY MARKET, 2016-2025  
(\$MILLION)**

**83 NETHERLANDS INJECTABLE DRUG DELIVERY MARKET, BY DEVICE,  
2016-2025 (\$MILLION)**

**84 SWITZERLAND INJECTABLE DRUG DELIVERY MARKET, 2016-2025  
(\$MILLION)**

**85 SWITZERLAND INJECTABLE DRUG DELIVERY MARKET, BY DEVICE,  
2016-2025 (\$MILLION)**

**86 BELGIUM INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**87 BELGIUM INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025  
(\$MILLION)**

**88 POLAND INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**89 POLAND INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025  
(\$MILLION)**

**90 AUSTRIA INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**91 AUSTRIA INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025  
(\$MILLION)**

**92 TURKEY INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**93 TURKEY INJECTABLE DRUG DELIVERY MARKET, BY DEVICE, 2016-2025  
(\$MILLION)**

**94 REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET, 2016-2025  
(\$MILLION)**

**95 REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DEVICE,  
2016-2025 (\$MILLION)**

**96 ASIA PACIFIC INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**97 JAPAN INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**98 JAPAN INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**99 CHINA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**100 CHINA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**101 AUSTRALIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**102 AUSTRALIA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES  
2016-2025 (\$MILLION)**

**103 SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET, BY VALUE,  
2016-2025 (\$MILLION)**

**104 SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES  
2016-2025 (\$MILLION)**

**105 INDIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**106 INDIA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**107 MALAYSIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**108 MALAYSIA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025**

**(\$MILLION)**

**109 INDONESIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**110 INDONESIA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**111 REST OF ASIA PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY VALUE,  
2016-2025 (\$MILLION)**

**112 REST OF ASIA PACIFIC INJECTABLE DRUG DELIVERY MARKET, BY  
DEVICES 2016-2025 (\$MILLION)**

**113 PREVALENCE OF DIABETES IN BRAZIL & MEXICO**

**114 LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, 2016-2025  
(\$MILLION)**

**115 BRAZIL INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**116 BRAZIL INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**117 MEXICO INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**118 MEXICO INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025  
(\$MILLION)**

**119 ARGENTINA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025  
(\$MILLION)**

**120 ARGENTINA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES  
2016-2025 (\$MILLION)**

**121 REST OF LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY  
VALUE, 2016-2025 (\$MILLION)**

**122 REST OF LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025 (\$MILLION)**

**123 ROW INJECTABLE DRUG DELIVERY MARKET, 2016-2025 (\$MILLION)**

**124 K.S.A INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**125 K.S.A INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025 (\$MILLION)**

**126 RUSSIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**127 RUSSIA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**128 SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**129 SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025 (\$MILLION)**

**130 ROW INJECTABLE DRUG DELIVERY MARKET, BY VALUE, 2016-2025 (\$MILLION)**

**131 ROW INJECTABLE DRUG DELIVERY MARKET, BY DEVICES 2016-2025 (\$MILLION)**

**132 ALKERMES PUBLIC LIMITED COMPANY: PRODUCT PORTFOLIO**

**133 ALKERMES PUBLIC LIMITED COMPANY: OVERALL FINANCIALS (2015-2017)**

**134 ALKERMES PUBLIC LIMITED COMPANY: REVENUE BY REGION (2015-2017)**

**135 ALKERMES PUBLIC LIMITED COMPANY: SWOT ANALYSIS**

**136 ANTARES PHARMA: OVERALL PRODUCT PORTFOLIO**

**137 ANTARES PHARMA: OVERALL FINANCIALS (2015-2017)**

**138 ANTARES PHARMA: PRODUCT SALES BY GEOGRAPHIC LOCATION  
(2015-2017)**

**139 ANTARES PHARMA: SWOT ANALYSIS**

**140 BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO**

**141 BAXTER INTERNATIONAL INC.: OVERALL FINANCIALS (2015-2017)**

**142 BAXTER INTERNATIONAL INC.: REVENUE BY GLOBAL BUSINESS  
UNITS(2015-2017)**

**143 BAXTER INTERNATIONAL INC.: REVENUE BY GEOGRAPHICAL LOCATION  
(2015-2017)**

**144 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS**

**145 BECTON DICKINSON AND COMPANY : OVERALL PRODUCT PORTFOLIO**

**146 BECTON, DICKINSON AND COMPANY : OVERALL FINANCIALS (2015-2017)**

**147 BECTON, DICKINSON AND COMPANY: PRODUCT SALES BY REGION  
(2015-2017)**

**148 BECTON, DICKINSON AND COMPANY: REVENUE BY BUSINESS SEGMENT  
(2015-2017)**

**149 BECTON, DICKINSON AND COMPANY: REVENUE BY SUB-SEGMENT  
(2015-2017)**

**150 BECTON DICKINSON AND COMPANY: SWOT ANALYSIS**

**151 ELCAM MEDICAL: PRODUCT PORTFOLIO**

**152 ELCAM MEDICAL: SWOT ANALYSIS**

**153 ELI-LILLY AND COMPANY: OVERALL PRODUCT PORTFOLIO**

**154 ELI-LILLY AND COMPANY: OVERALL FINANCIALS (2014-2017)**

**155 ELI-LILLY AND COMPANY : REVENUE BY BUSINESS SEGMENT (2014-2017)**

**156 ELI-LILLY AND COMPANY: REVENUE BY GEOGRAPHY (2014-2017)**

**157 ELI-LILLY AND COMPANY: SWOT ANALYSIS**

**158 GERRESHEIMER AG: OVERALL PRODUCT PORTFOLIO**

**159 GERRESHEIMER AG: OVERALL FINANCIALS (2015-2017)**

**160 GERRESHEIMER AG: REVENUE BY BUSINESS DIVISION (2015-2017)**

**161 GERRESHEIMER AG: REVENUE BY GEOGRAPHICAL LOCATION (2015-2017)**

**162 GERRESHEIMER AG: SWOT ANALYSIS**

**163 INJEX PHARMA GMBH: PRODUCT PORTFOLIO**

**164 INJEX PHARMA GMBH: SWOT ANALYSIS**

**165 NOVARTIS AG.: OVERALL PRODUCT PORTFOLIO**

**166 NOVARTIS AG : OVERALL FINANCIALS (2014-2017)**

**167 NOVARTIS AG : REVENUE BY REGION (2014-2017)**

**168 NOVARTIS AG: REVENUE BY BUSINESS SEGMENT (2014-2015)**

**169 NOVARTIS AG: REVENUE BY BUSINESS SEGMENT (2016-2017)**

**170 NOVARTIS AG: SWOT ANALYSIS**

**171 NOVO NORDISK: OVERALL PRODUCT PORTFOLIO**

**172 NOVO NORDISK: OVERALL FINANCIALS (2015-2017)**



**173 NOVO NORDISK: REVENUE BY BUSINESS SEGMENT (2015-2017)**

**174 NOVO NORDISK: PRODUCT SALES BY GEOGRAPHICAL AREAS (2015-2017)**

**175 NOVO NORDISK: SWOT ANALYSIS**

**176 PFIZER, INC.: PRODUCT PORTFOLIO**

**177 PFIZER INJECTABLES: PRODUCT PORTFOLIO**

**178 PFIZER INC. : OVERALL FINANCIALS (2015-2017)**

**179 PFIZER INC. : REVENUE BY BUSINESS SEGMENT (2015-2017)**

**180 PFIZER, INC. : REVENUE BY GEOGRAPHY (2015-2017)**

**181 PFIZER, INC. : SWOT ANALYSIS**

**182 PHARMAJET: PRODUCT PORTFOLIO**

**183 PHARMAJET: SWOT ANALYSIS**

**184 SANOFI: OVERALL PRODUCT PORTFOLIO**

**185 SANOFI: OVERALL FINANCIALS (2015-2017)**

**186 SANOFI: REVENUE BY BUSINESS SEGMENT (2015)**

**187 SANOFI: REVENUE BY BUSINESS SEGMENT (2016-2017)**

**188 SANOFI: REVENUE BY GEOGRAPHY (2016-2017)**

**189 SANOFI: REVENUE BY GEOGRAPHY (2015)**

**190 SANOFI: SWOT ANALYSIS**

**191 SCHOTT AG: OVERALL PRODUCT PORTFOLIO**

**192 SCHOTT AG: OVERALL FINANCIALS (2015-2017)**

**193 SCHOTT AG: REVENUE BY GEOGRAPHICAL LOCATION (2016-2017)**

**194 SCHOTT AG: REVENUE BY GEOGRAPHICAL LOCATION(2015)**

**195 SCHOTT AG: SWOT ANALYSIS**

**196 TERUMO CORPORATION: OVERALL PRODUCT PORTFOLIO**

**197 TERUMO PHARMACEUTICAL SOLUTIONS: PRODUCT PORTFOLIO**

**198 TERUMO CORPORATION: OVERALL FINANCIALS (2015-2017)**

**199 TERUMO CORPORATION: REVENUE BY BUSINESS SEGMENT (2015-2017)**

**200 TERUMO CORPORATION: NET REVENUE BY REGION (2015-2017)**

**201 TERUMO CORPORATION: SWOT ANALYSIS**

**202 TEVA PHARMACEUTICALS INDUSTRIES LIMITED: PRODUCT PORTFOLIO**

**203 TEVA PHARMACEUTICALS INDUSTRIES LIMITED.: OVERALL FINANCIALS (2015-2017)**

**204 TEVA PHARMACEUTICALS INDUSTRIES LIMITED.: REVENUE BY BUSINESS SEGMENTS (2015-2017)**

**205 TEVA PHARMACEUTICALS INDUSTRIES LIMITED.: REVENUE BY GEOGRAPHICAL LOCATION (2015-2017)**

**206 TEVA PHARMACEUTICALS INDUSTRIES LIMITED.: SWOT ANALYSIS**

**207 VETTER PHARMA-FERTIGUNG GMBH & CO. KG: PRODUCT PORTFOLIO**

**208 VETTER PHARMA-FERTIGUNG GMBH & CO. KG: SWOT ANALYSIS**

**209 WEST PHARMACEUTICAL SERVICES, INC.: OVERALL PRODUCT PORTFOLIO**

**210 WEST PHARMACEUTICAL SERVICES, INC.: OVERALL FINANCIALS  
(2015-2017)**

**211 WEST PHARMACEUTICAL SERVICES, INC.: REVENUE BY BUSINESS  
SEGMENT (2015-2017)**

**212 WEST PHARMACEUTICAL SERVICES, INC.: REVENUE BY GEOGRAPHICAL  
LOCATION (2015-2017)**

**213 WEST PHARMACEUTICAL SERVICES, INC.: SWOT ANALYSIS**

**214 YPSOMED HOLDING AG: PRODUCT PORTFOLIO**

**215 YPSOMED HOLDING AG: OVERALL FINANCIALS (2015-2017)**

**216 YPSOMED HOLDING AG: REVENUE BY BUSINESS SEGMENTS (2015-2017)**

**217 YPSOMED HOLDING AG: REVENUE BY GEOGRAPHICAL LOCATION  
(2015-2017)**

**218 YPSOMED HOLDING AG: SWOT ANALYSIS**

**219 GLOBAL INJECTABLE DRUG DELIVERY MARKET SEGMENTATION**

## I would like to order

Product name: Global Injectable Drug Delivery Market – Focus on Devices, Competitive Landscape and Country - Analysis and Forecast (2018-2025)

Product link: <https://marketpublishers.com/r/GE35725F2814EN.html>

Price: US\$ 4,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE35725F2814EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

